YTB323 for non-active progressive MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new treatment called YTB323, which is a type of personalized cell therapy (CAR-T) designed to target your immune system and slow down MS progression. It is for people with non-active progressive MS who have seen their disability worsen recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with secondary progressive or primary progressive MS (non-active form) for less than 15 years.
- Your disability score (EDSS) is between 3.0 and 6.5, meaning you can still walk but may need a cane or walker.
- Your MS has worsened by at least 1 point on the disability scale in the last 2 years, but you have not had any relapses in that time.
- You have no active inflammation on your most recent MRI (no gadolinium-enhancing lesions).
- You are willing to undergo a lumbar puncture (spinal tap) and multiple MRIs, and you are up to date on all recommended vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called obe-cel, a type of CAR T-cell therapy, for people with progressive multiple sclerosis that hasn't responded to other treatments. It aims to see if this therapy can slow or stop the disease from getting worse.
This trial tests a new cell therapy called YTB323 for people with relapsing multiple sclerosis (RMS) that is still active despite strong treatments. The treatment aims to reset the immune system to stop attacks on nerves.
This trial tests a new CAR-T cell therapy (YTB323) for people with generalized myasthenia gravis that hasn't been well-controlled by standard treatments. The goal is to see if it can safely improve symptoms and change how the immune system attacks the nerves.
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
Hear when a new Progressive Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.